These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 18201769)
21. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Eccles SA; Modjtahedi H; Box G; Court W; Sandle J; Dean CJ Invasion Metastasis; 1994-1995; 14(1-6):337-48. PubMed ID: 7657527 [TBL] [Abstract][Full Text] [Related]
22. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Chen FL; Xia W; Spector NL Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964 [TBL] [Abstract][Full Text] [Related]
28. [Present status and future prospects of antibody therapy against solid tumor]. Saijo N Nihon Rinsho; 2012 Dec; 70(12):2051-7. PubMed ID: 23259374 [TBL] [Abstract][Full Text] [Related]
29. State of the art in anti-cancer mAbs. Chiavenna SM; Jaworski JP; Vendrell A J Biomed Sci; 2017 Feb; 24(1):15. PubMed ID: 28219375 [TBL] [Abstract][Full Text] [Related]
30. A target for tumour-directed therapy. Hynes NE; Groner B Nat Med; 1995 Jul; 1(7):631. PubMed ID: 7585140 [No Abstract] [Full Text] [Related]
32. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Hosseini M; Haji-Fatahaliha M; Jadidi-Niaragh F; Majidi J; Yousefi M Artif Cells Nanomed Biotechnol; 2016 Jun; 44(4):1051-61. PubMed ID: 25612903 [TBL] [Abstract][Full Text] [Related]
33. Antibody-based immunological therapies. Scott AM; Welt S Curr Opin Immunol; 1997 Oct; 9(5):717-22. PubMed ID: 9368782 [TBL] [Abstract][Full Text] [Related]
34. Natural and therapy-induced immunosurveillance in breast cancer. Kroemer G; Senovilla L; Galluzzi L; André F; Zitvogel L Nat Med; 2015 Oct; 21(10):1128-38. PubMed ID: 26444637 [TBL] [Abstract][Full Text] [Related]
35. Recent developments in antibody derivatives against colorectal cancer; A review. Ghani S; Bahrami S; Rafiee B; Eyvazi S; Yarian F; Ahangarzadeh S; Khalili S; Shahzamani K; Jafarisani M; Bandehpour M; Kazemi B Life Sci; 2021 Jan; 265():118791. PubMed ID: 33220288 [TBL] [Abstract][Full Text] [Related]
37. Keystone symposia: antibody-based therapeutics for cancer. Power B; Hudson P Expert Opin Biol Ther; 2003 Apr; 3(2):385-9. PubMed ID: 12662151 [TBL] [Abstract][Full Text] [Related]
38. Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials. Yuan Y; Chen J; Fang M; Guo Y; Sun X; Yu D; Guo Y; Xin Y Front Oncol; 2022; 12():994726. PubMed ID: 36263226 [TBL] [Abstract][Full Text] [Related]
39. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook. Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H Front Immunol; 2022; 13():887471. PubMed ID: 35935930 [TBL] [Abstract][Full Text] [Related]
40. From antibodies to living drugs: Quo vadis cancer immunotherapy? Szöőr Á; Szöllősi J; Vereb G Biol Futur; 2021 Mar; 72(1):85-99. PubMed ID: 34554498 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]